enGene reports FY2024 net loss $55.1M; cash $297.9M; LEGEND study on track for mid-2026 BLA

enGene Therapeutics Inc.

2024-FY EPS reported $1.46

Net loss $55.1M ($1.46/sh) vs $104.7M in FY2023; operating expenses $62.3M up from $26.1M.
Cash, cash equivalents and marketable securities $297.9M; expected to fund operations into 2027.
Preliminary LEGEND pivotal data: 71% anytime CR rate in BCG-unresponsive NMIBC with CIS; BLA filing on track for mid-2026.
First Amendment with Hercules Capital reallocates $7.5M to Tranche 3; total $50M facility unchanged.
Appointed Joan Connolly as CTO, Anthony Cheung as CSO, Alex Nichols as Chief Strategy & Operations Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.